M Karpusas1, A Whitty, L Runkel
1Biogen Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA. michael_karpusas@biogen.com
Human Interferon-beta (HuIFN-beta) structure reveals glycosylation is key to its stability and therapeutic activity. Understanding its protein structure aids in developing Type I interferons for clinical applications.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: